Ker-ching!

Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.

Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.

Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.

Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.

Tags: Radiation, Contract

Our Current Sponsors

  • 908 Devices
  • Airboss
  • Argon
  • Avon
  • Battelle
  • Biofire Idaho
  • Bruker
  • Bw Tek
  • Cap Force 1 Decon 01
  • CQC
  • Cristanini
  • Decon Seven Systems
  • DQE
  • Dxterity
  • Emergent Biosol
  • Endeavor Roborics
  • Ecotest
  • Federal Resources
  • First Line Technology
  • Flir
  • Futurtech
  • Hameln
  • Metrohm Raman
  • NBC sys
  • Proengin
  • Qinetiq
  • RSDecon
  • Tex Shield
  • Wl Gore